Abeliovich Asa 4
4 · Prevail Therapeutics Inc. · Filed Jan 26, 2021
Insider Transaction Report
Form 4
Abeliovich Asa
DirectorPresident & CEO10% Owner
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−178,681→ 0 totalExercise: $10.26→ Common Stock (178,681 underlying) - Disposition from Tender
Common Stock
2021-01-22−2,385,756→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−1,329,219→ 0 totalExercise: $0.18→ Common Stock (1,329,219 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−250,000→ 0 totalExercise: $16.91→ Common Stock (250,000 underlying)
Footnotes (2)
- [F1]Pursuant to the terms of the Merger Agreement, these shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive (i) $22.50 per share of common stock, net to the seller in cash, without interest (the "Closing Amount"), plus (ii) one contingent value right per share (a "CVR"), which shall represent the right to receive certain consideration based on the achievement of net sales milestones.
- [F2]Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of the Issuer's common stock, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of the Closing Amount over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one CVR for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).